Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation

Role of maintenance endocrine therapy

F. Montemurro, G. Rondón, N. T. Ueno, M. Munsell, J. L. Gajewski, R. E. Champlin

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

We retrospectively analyzed the effect of maintenance endocrine therapy (MET) after high-dose chemotherapy with hematopoietic progenitor cell transplant (HDCT) on the progression-free survival (PFS) of patients with hormone-dependent metastatic breast cancer (MBC). One hundred and nine consecutive patients with estrogen receptor (ER) and/or progesterone receptor (PgR)-positive MBC, who were progression free for at least 4 months after HDCT with cyclophosphamide, carmustine and thiotepa (CBT), were analyzed. Of these, 55 were non-randomly submitted to MET. After a median follow-up of 34.4 months (17.1-91.0), univariate analysis showed that MET was significantly associated with improved median PFS (31.1 vs 19.2 months, P = 0.022). Complete response to HDCT, pattern of metastatic spread, extent of the disease, single vs multiple metastatic sites, prior endocrine therapy for metastatic disease and prior exposure to any hormonal therapy (adjuvant and/or for the advanced disease) were also associated with PFS at univariate analysis. A multivariate Cox proportional hazard model was fitted to the data in order to correct the effect of MET for the other significant covariates. After correcting for these covariates, MET was still significant, predicting improved PFS (hazard ratio (HR) 0.580, 95% CI; 0.362-0.931). Administration of MET after optimal cytoreduction might result in increased efficacy of HDCT in hormone-dependent metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)861-866
Number of pages6
JournalBone Marrow Transplantation
Volume29
Issue number10
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Cell Transplantation
Hematopoietic Stem Cells
Disease-Free Survival
Maintenance
Hormones
Breast Neoplasms
Drug Therapy
Therapeutics
Thiotepa
Carmustine
Progesterone Receptors
Proportional Hazards Models
Estrogen Receptors
Cyclophosphamide
Transplants

Keywords

  • Breast neoplasm
  • Hematopoietic stem cell transplantation
  • Hormonal therapy
  • Maintenance endocrine therapy
  • Metastatic

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation : Role of maintenance endocrine therapy. / Montemurro, F.; Rondón, G.; Ueno, N. T.; Munsell, M.; Gajewski, J. L.; Champlin, R. E.

In: Bone Marrow Transplantation, Vol. 29, No. 10, 2002, p. 861-866.

Research output: Contribution to journalArticle

@article{8ed48b64ae4b4d0189dabc33c45ef77f,
title = "Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: Role of maintenance endocrine therapy",
abstract = "We retrospectively analyzed the effect of maintenance endocrine therapy (MET) after high-dose chemotherapy with hematopoietic progenitor cell transplant (HDCT) on the progression-free survival (PFS) of patients with hormone-dependent metastatic breast cancer (MBC). One hundred and nine consecutive patients with estrogen receptor (ER) and/or progesterone receptor (PgR)-positive MBC, who were progression free for at least 4 months after HDCT with cyclophosphamide, carmustine and thiotepa (CBT), were analyzed. Of these, 55 were non-randomly submitted to MET. After a median follow-up of 34.4 months (17.1-91.0), univariate analysis showed that MET was significantly associated with improved median PFS (31.1 vs 19.2 months, P = 0.022). Complete response to HDCT, pattern of metastatic spread, extent of the disease, single vs multiple metastatic sites, prior endocrine therapy for metastatic disease and prior exposure to any hormonal therapy (adjuvant and/or for the advanced disease) were also associated with PFS at univariate analysis. A multivariate Cox proportional hazard model was fitted to the data in order to correct the effect of MET for the other significant covariates. After correcting for these covariates, MET was still significant, predicting improved PFS (hazard ratio (HR) 0.580, 95{\%} CI; 0.362-0.931). Administration of MET after optimal cytoreduction might result in increased efficacy of HDCT in hormone-dependent metastatic breast cancer.",
keywords = "Breast neoplasm, Hematopoietic stem cell transplantation, Hormonal therapy, Maintenance endocrine therapy, Metastatic",
author = "F. Montemurro and G. Rond{\'o}n and Ueno, {N. T.} and M. Munsell and Gajewski, {J. L.} and Champlin, {R. E.}",
year = "2002",
doi = "10.1038/sj.bmt.1703555",
language = "English (US)",
volume = "29",
pages = "861--866",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation

T2 - Role of maintenance endocrine therapy

AU - Montemurro, F.

AU - Rondón, G.

AU - Ueno, N. T.

AU - Munsell, M.

AU - Gajewski, J. L.

AU - Champlin, R. E.

PY - 2002

Y1 - 2002

N2 - We retrospectively analyzed the effect of maintenance endocrine therapy (MET) after high-dose chemotherapy with hematopoietic progenitor cell transplant (HDCT) on the progression-free survival (PFS) of patients with hormone-dependent metastatic breast cancer (MBC). One hundred and nine consecutive patients with estrogen receptor (ER) and/or progesterone receptor (PgR)-positive MBC, who were progression free for at least 4 months after HDCT with cyclophosphamide, carmustine and thiotepa (CBT), were analyzed. Of these, 55 were non-randomly submitted to MET. After a median follow-up of 34.4 months (17.1-91.0), univariate analysis showed that MET was significantly associated with improved median PFS (31.1 vs 19.2 months, P = 0.022). Complete response to HDCT, pattern of metastatic spread, extent of the disease, single vs multiple metastatic sites, prior endocrine therapy for metastatic disease and prior exposure to any hormonal therapy (adjuvant and/or for the advanced disease) were also associated with PFS at univariate analysis. A multivariate Cox proportional hazard model was fitted to the data in order to correct the effect of MET for the other significant covariates. After correcting for these covariates, MET was still significant, predicting improved PFS (hazard ratio (HR) 0.580, 95% CI; 0.362-0.931). Administration of MET after optimal cytoreduction might result in increased efficacy of HDCT in hormone-dependent metastatic breast cancer.

AB - We retrospectively analyzed the effect of maintenance endocrine therapy (MET) after high-dose chemotherapy with hematopoietic progenitor cell transplant (HDCT) on the progression-free survival (PFS) of patients with hormone-dependent metastatic breast cancer (MBC). One hundred and nine consecutive patients with estrogen receptor (ER) and/or progesterone receptor (PgR)-positive MBC, who were progression free for at least 4 months after HDCT with cyclophosphamide, carmustine and thiotepa (CBT), were analyzed. Of these, 55 were non-randomly submitted to MET. After a median follow-up of 34.4 months (17.1-91.0), univariate analysis showed that MET was significantly associated with improved median PFS (31.1 vs 19.2 months, P = 0.022). Complete response to HDCT, pattern of metastatic spread, extent of the disease, single vs multiple metastatic sites, prior endocrine therapy for metastatic disease and prior exposure to any hormonal therapy (adjuvant and/or for the advanced disease) were also associated with PFS at univariate analysis. A multivariate Cox proportional hazard model was fitted to the data in order to correct the effect of MET for the other significant covariates. After correcting for these covariates, MET was still significant, predicting improved PFS (hazard ratio (HR) 0.580, 95% CI; 0.362-0.931). Administration of MET after optimal cytoreduction might result in increased efficacy of HDCT in hormone-dependent metastatic breast cancer.

KW - Breast neoplasm

KW - Hematopoietic stem cell transplantation

KW - Hormonal therapy

KW - Maintenance endocrine therapy

KW - Metastatic

UR - http://www.scopus.com/inward/record.url?scp=0035998367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035998367&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1703555

DO - 10.1038/sj.bmt.1703555

M3 - Article

VL - 29

SP - 861

EP - 866

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 10

ER -